Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06446180
Other study ID # 2024-002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 31, 2024
Est. completion date May 20, 2024

Study information

Verified date June 2024
Source The General Hospital of Western Theater Command
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radiation-induced oral mucositis (RIOM) is the most common oral complication of cancer patients receiving radiotherapy and/or chemotherapy, leading to poor quality of life. the investigators previous studies that have reported the use of single SSK12 probiotics in RIOM. However, SSK12 probiotics alone may lack stability, free radical scavenging activity and oral local targeting.Here, the investigators designed a new oral probiotic K12@Lip@GSH that SSK12 is encapsulated in liposomes(Lip) to enhance its stability and free radical scavenging ability, and glutathione (GSH) transporter-mediated oral targeting agent based on the over-expression of GSH transporters at the RIOM. The investigators have complete evaluated the treatment outcome of SSK12@Lip@GSH on RIOM mice. The investigators designed a single-center, single-arm prospective clinical study to evaluate the efficacy and safety of SsK12@Lip@GSH in the treatment of radioactive oral mucositis in patients with head and neck malignancies


Description:

Radiotherapy (RT) is an important method of treatment for malignant tumors of the head and neck and can be used alone or in combination with chemotherapy as a radical or adjuvant therapy. Despite improvements in RT equipment and techniques, various acute oral complications persist, including oral mucositis (OM), dry mouth, taste dysfunction, and oral infections. OM is one of the most common acute radiation-related toxicities, and approximately 50%-70% of patients experience severe OM (SOM) defined by the WHO scale as grade 3 to 4. The painful inflammation and ulceration associated with OM not only profoundly affect patients' ability to eat, swallow, and speak, but also decrease their tolerance to anti-cancer treatment, thereby, impairing their quality of life (QoL) significantly and causing interruptions in their cancer treatment. Although some clinical strategies for radiation-induced OM have been recommended by the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) , their efficacy and safety still need further clinical validation. Recent evidence suggests the involvement of oral microbiota in radiationinduced OM, and modulation of oral microbiota is promising for the management of OM. Streptococcus salivarius K12 is a commercially available oral probiotic with strong oral colonization ability, bacteriocin-like inhibitory substance (BLIS)-producing capability, and immunomodulatory properties, and has been used to treat oral candidiasis, pharyngitis, tonsillitishalitosis, and otitis media. More importantly, data from our recent animal study demonstrated that topical use of S. salivarius K12 ameliorates radiationinduced OM in mice by modulating the oral microbiota, mainly by suppressing oral anaerobes. the investigatorsprevious studies that have reported the use of single SSK12 probiotics in RIOM. In 2024, the applicant team published a randomized controlled trial as the first author in the top journal in the field of oncology, Journal o f Clinical Oncology, which found that Streptococcus salivarius K12 (SSK12) can effectively alleviate RIOM in radiotherapy patients with malignant head and neck tumors. However, SSK12 probiotics alone may lack stability, free radical scavenging activity and oral local targeting.Here, the investigators designed a new oral probiotic K12@Lip@GSH that SSK12 is encapsulated in liposomes(Lip) to enhance its stability and free radical scavenging ability, and glutathione (GSH) transporter-mediated oral targeting agent based on the over-expression of GSH transporters at the RIOM. the investigators evaluated the treatment outcome of SSK12@Lip@GSH on RIOM mice . In vitro studies showed that SSK12@Lip@GSH treatment was beneficial for the healing of RIOM mice, as reflected by reduced ulcer size, increased basal layer epithelial cellularity and mucosal thickness, and elevated epithelial proliferation and attenuated apoptosis. Genomic results showed that the SSK12@Lip@GSH could improve relevant mRNA pathways to promote RIOM healing. In addition, SSK12@Lip@GSH treatment reconstituted the oral microbiota and decreased the abundance of oral anaerobes of RIOM mice.Therefore, the SSK12@Lip@GSH holds promise as a potential approach for preventing and treating radiation-induced oral mucositis.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 20, 2024
Est. primary completion date March 21, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 1. Patients pathologically diagnosed with non-metastatic head and neck malignant tumors; - 2. Aged 18-80 years; - 3. Eastern Cooperative Oncology Group performance status of =2; - 4. Planning to receive definitive RT or postoperative adjuvant RT; - 5. Normal liver, kidney and bone marrow function; - 6. Sign informed consent. Exclusion Criteria: - 1.Known hypersensitivity or more severe allergies to Lactobacillus Reuteri components; - 2.Those with poor compliance; - 3.Pregnancy or breastfeeding; - 4.History of head and neck radiotherapy; - 5.Taking antifungal or viral medications one week prior to the start of radiation therapy. - 6.Other patients (with any other serious other medical condition) who, in the opinion of the investigator, are not suitable for participation in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
SsK12@Lip@GSH
SsK12@Lip@GSH powder contained no less than 5×10^8 CFU viable cells of SsK12@Lip@GSH as the active ingredient.

Locations

Country Name City State
China Department of Oncology,The General Hospital of Western Theater Command Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
The General Hospital of Western Theater Command

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of Severe Oral mucositis (WHO grade =3) Oral mucositis is assessed by trained physicians according to World Health Organization (WHO) oral toxicity Scale.The WHO Oral Toxicity Scale categorizes oral mucositis into grades 0-4, with the higher the grade the more severe the patient's oral mucositis. Grade 0 means that the oral mucosa is normal and the patient has no symptoms or signs; grade 1 means that the mucosa is erythematous with or without pain and does not interfere with eating; grade 2 means that the mucosa is erythematous and ulcerated, but still able to eat solid food; grade 3 means that the mucosa is severely ulcerated with extensive erythema and unable to eat solid food; and grade 4 means that the ulcers of the mucosa are fused together into a sheet, and their severity is so severe that it is not possible to eat. From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary The time to onset of Severe Oral mucositis (WHO grade =3) Time from the first day of radiotherapy to the first determination of SOM. Patients without observed SOM were assigned onset days of 6 or 6.5 weeks From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary The duration of Severe Oral mucositis (WHO grade =3) The first determination of SOM to the first instance of non-severe OM (WHO grade <3), without a subsequent instance of SOM. Patients without observed SOM were assigned a duration of 0 days From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary Mouth and throat soreness (MTS) scores Patients report mouth and throat soreness (MTS) scores (Likert scale 1 to 5) via the oral mucositis weekly questionnaire (OMWQ). Higher score indicates more severe symptoms From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary Xerostomia summated xerostomia inventory (SXI) Xerostomia is subjectively assessed on the Summated Xerostomia Inventory (SXI). The SXI is categorized according to score as 0 no dry mouth (5), 1 mild dry mouth (6-8), 2 moderate dry mouth (9-12), and 3 severe (13-15). From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary Functional assessment of cancer therapy-head and neck (FACT- H&N) quality of life questionnaire FACT- H&N quality of life questionnaire 4.0 is a scale used to assess quality of life in From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary Adverse events Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary Oral activities scores Patients report the degree to the impact of MTS on oral activities (including swallowing, drinking, eating, talking, sleeping) (Likert scale 1 to 5) via the oral mucositis weekly questionnaire (OMWQ). Higher score indicates more severe symptoms From the start of radiotherapy to 4 weeks after completion of radiotherapy
See also
  Status Clinical Trial Phase
Completed NCT02229136 - Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus Phase 2
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Enrolling by invitation NCT02662374 - Oral Hygiene Regimen in Patients on HCT Phase 4
Completed NCT00938080 - Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck Phase 1
Completed NCT00756951 - Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer Phase 2
Completed NCT00701688 - Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Not yet recruiting NCT05059613 - Thalidomide With or Without Probiotics in Radioactive Oral Mucositis N/A
Completed NCT04440930 - White Tea for Prevention of Chemotherapy Induced Mucositis N/A
Completed NCT05705622 - The Effect of Nursing Education on Oral Mucositis in Bone Marrow Transplant Patients N/A
Completed NCT02399228 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis Phase 2
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Enrolling by invitation NCT06122636 - Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC N/A
Completed NCT03689712 - ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients Phase 3
Terminated NCT02539342 - Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy Phase 3
Completed NCT02555501 - Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy Phase 3
Completed NCT01789658 - Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation N/A
Completed NCT00790322 - Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy Phase 3
Recruiting NCT00549952 - Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients N/A
Completed NCT00289003 - The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients Phase 2